If you’ve been on semaglutide for a while, you already know the math: the medication works, but the price doesn’t. In the US, a single box of Wegovy runs close to $1,000 out of pocket. Without insurance, a full year of treatment can cost over $10,000. For most people in the world — and even for many Americans — that number has simply meant “no.”
That’s about to change. And faster than most expected.
The Patent Wall Just Cracked
On March 21, 2026, Novo Nordisk’s patent protection on semaglutide — the active ingredient in both Ozempic and Wegovy — expired in India, China, Canada, Brazil, Turkey, and South Africa. (NordiskPost)
This isn’t a rumor or a projection. It happened. And the generics industry moved the moment it did.
In India alone, over 40 pharmaceutical companies had been preparing for this moment, with more than 50 branded generic versions lined up and ready to go. (NordiskPost)
How Cheap Are We Talking?
Very cheap. Researchers have shown that generic injectable semaglutide can be manufactured for between $28 and $140 per person per year — that’s roughly $3 a month. (STAT News)
To understand just how stark that gap is: the raw active pharmaceutical ingredient in a single dose of semaglutide costs about $0.12 at the highest maintenance dose. The injection pen it comes in costs between $0.30 and $2.50 to produce. (ZME Science)
The rest of what you’ve been paying? Mostly patents, branding, and profit margin.
In India, real-world prices are already reflecting this shift:
- Sun Pharmaceutical launched generic semaglutide at 750 rupees (~$8) per weekly injection, or about 3,400 rupees per month — compared to Novo Nordisk’s 8,800–10,000 rupees. (CNBC)
- Natco Pharma and Alkem Laboratories are offering discounts of nearly 80% off Novo’s price. (CNBC)
- Dr. Reddy’s Laboratories launched at around 4,200 rupees per month and has plans to expand into Canada, Turkey, and Brazil this year. (CNBC)
Analysts predict that as competition intensifies, prices in some countries could eventually fall to $15 a month. (Detroit News)
Why This Matters Beyond the Price Tag
The countries where patents expired this month — India, China, Canada, Brazil — carry a disproportionate share of the world’s metabolic disease burden. Together, they account for 69% of global type 2 diabetes cases and 84% of clinical obesity cases. (ZME Science)
Researchers estimate that affordable generic semaglutide could reach 160 countries, with the potential to transform access to obesity and diabetes treatment for billions of people. (ZME Science)
That’s not a small deal. That’s a public health inflection point.
What About Canada?
Canada is in a unique position. Patent protection weakened in early 2026, and Sandoz — one of the world’s largest generics manufacturers — was already planning a first-quarter launch. Prices there are projected to drop by around 65% from current branded levels. (Felix Health)
Regulatory timing may still delay when generic semaglutide actually hits pharmacy shelves, but the direction is clear. (NordiskPost)
And the US?
Here’s the frustrating part if you’re American: the US and Europe are protected by additional regulatory layers that extend Novo Nordisk’s exclusivity into the early 2030s. Full generic competition in the US market is still years away.
What you can do in the meantime:
- Check insurance coverage — many plans now cover GLP-1s, especially if prescribed for diabetes or cardiovascular risk
- Use manufacturer savings cards — Novo Nordisk offers programs that can reduce out-of-pocket cost significantly for eligible patients
- Avoid unregulated compounding pharmacies — the FDA took enforcement action in March 2026 against 30 telehealth companies selling compounded GLP-1s, clarifying these are not generics and are unapproved (Science-Based Medicine)
What Novo Nordisk Is Doing About It
Novo isn’t sitting still. The company is betting that brand loyalty and the superior delivery experience of its auto-injector pens will keep patients — especially in higher-income markets — choosing Ozempic and Wegovy over generic alternatives.
They also hold more than 220 patents across 20 patent “families,” many protecting specific formulations and pen mechanisms rather than the drug molecule itself. This means even where semaglutide goes off-patent, generic manufacturers still need to engineer around device patents. (ZME Science)
Still, Novo Nordisk has acknowledged the financial reality. The company warned that patent expirations in India, Canada, Brazil, and China could cause sales to decline by 5% to 13% in 2026. (Advisor Perspectives)
The Bottom Line for Our Community
If you’re on GLP-1 medication right now, you’re living through one of the most significant pharmaceutical transitions of this decade. The drug that changed your life — the one that felt impossibly out of reach for so many — is becoming affordable for billions.
That doesn’t fix the US access problem today. But the trajectory is undeniable.
Generic semaglutide is no longer a hypothetical. It’s on pharmacy shelves in India right now, at a fraction of the price. Canada is next. And the rest of the world is watching.
We’ll keep tracking this closely at LifeOnGLP — because access to this medication isn’t just a business story. It’s personal.
Sources: NYT · CNBC · STAT News · ZME Science · NordiskPost · Advisor Perspectives · Felix Health · Detroit News · Science-Based Medicine